Cancer Immunotherapy Market Growth: Size, Key Trends, Demand & Forecast 2026-2034

Market Overview

According to IMARC Group's latest research publication, "Cancer Immunotherapy Market Size, Share, Trends and Forecast by Therapy Type, Application, End User, and Region, 2026-2034", the global cancer immunotherapy market size reached USD 140.5 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 284.1 Billion by 2034, exhibiting a growth rate (CAGR) of 7.89% during 2026-2034.

This detailed analysis primarily encompasses industry size, business trends, market share, key growth factors, and regional forecasts. The report offers a comprehensive overview and integrates research findings, market assessments, and data from different sources. It also includes pivotal market dynamics like drivers and challenges, while also highlighting growth opportunities, financial insights, technological improvements, emerging trends, and innovations. Besides this, the report provides regional market evaluation, along with a competitive landscape analysis.

How Precision Oncology is Reshaping the Future of Cancer Immunotherapy Market

• According to the International Agency for Research on Cancer, approximately 19.29 Million cancer cases had been estimated, and those cases are anticipated to grow up to 24.58 Million cases.

• GLOBOCAN shows that approximately 2,281,658 new cancer cases were diagnosed and 612,390 deaths due to cancer alone in the United States.

• According to the National Clinical Trials (NCT) Registry, there are more than 1,000 ongoing clinical trials worldwide for the development of cancer treatment with immune-based therapies.

• In July 2023, "Quizartinib (Vanflyta)" was approved by FDA as an advanced treatment against acute myeloid leukemia, targeting FLT3.

• In August 2023, the FDA authorised Talvey to treat adult patients with relapsed or refractory multiple myeloma who have had at least four lines of treatment.

Grab a sample copy of this report: https://www.imarcgroup.com/cancer-immunotherapy-market/requestsample

Key Trends in the Cancer Immunotherapy Market

• Increasing Prevalence of Cancer: The primary reason that is driving the market for cancer immunotherapies is the increasing cancer cases globally. According to the International Agency for Research on Cancer, approximately 19.29 Million cancer cases had been estimated, and those cases are anticipated to grow up to 24.58 Million cases. So, that much growth of cancer cases is adding to the demand for effective treatment solutions such as immunotherapy. GLOBOCAN shows that approximately 2,281,658 new cancer cases were diagnosed and 612,390 deaths due to cancer alone in the United States. Other than this, lung cancer and breast cancer are two of the most common cancers found in individuals. The Canadian Cancer Society (CCS) reported that nearly 29,800 Canadians were diagnosed with lung cancer, which accounted for 13% of all new cancer cases. Approximately 21,200 Canadians were expected to die from lung cancer, which comprised 25% of all cancer deaths. This reflects an increasing demand for effective and more sophisticated cancer immunotherapy. Therefore, growing demand for effective and long-term cancer treatment is expected to present attractive growth opportunities to the market in general.

• Rising Approval of Novel Immunotherapies: There are several key market players who are heavily investing in research and development (R&D) activities to develop and introduce advanced and more effective immunotherapies. According to the National Clinical Trials (NCT) Registry, there are more than 1,000 ongoing clinical trials worldwide for the development of cancer treatment with immune-based therapies. Furthermore, officials and responsible regulators of many nations are trying to hasten the clearance process of advanced immunotherapies and hence it is expected to provide more fuel to the business in question. For example, "Quizartinib (Vanflyta)," in July 2023, has been approved by FDA as an advanced treatment against the acute myeloid leukemia phase of newly diagnosed acute myeloid leukemia that covers various phases. Quizartinib targets FLT3, one of the kinases that becomes scrambled in approximately one-third of AML cases.

• Partnerships and Collaborations between Pharmaceuticals and Research Institutions: There are a number of strategic activities by key players launching new products. In this respect, Immatics and Moderna have collaborated strategically to develop oncology therapeutics. The collaboration includes an evaluation of Immatics' investigational PRAME203 TCRT in confluence with the MARTE mRNA cancer vaccine under development by Moderna. In addition, FBD Biologics Limited and Shanghai Henlius Biotech, Inc. announced a strategic collaboration to strengthen the development of new immunotherapies. Likewise, BioMed X, a German research institution, launched a new joint research project with Ono Pharmaceutical Co. Ltd., a Japanese pharmaceutical company, to design next-generation immunotherapies based on the antitumor effects of neutrophils. The Partnership for Accelerating Cancer Therapies, a five-year public-private research collaboration of USD 220 Million, aims to advance immune therapies for cancer. PACT has been working on identifying, developing, and validating strong biomarkers to enhance the therapies that tap the power of the immune system to combat cancer, with more than 37 clinical trials and 4,000 planned participants across 15+ types of cancers. Such collaborations, along with merger and acquisition activities by companies like Amgen Inc., AstraZeneca plc, Bayer AG, and Eli Lilly and Company, are expected to further augment the revenue of the market in the coming future.

• Advancements in Diagnostics and Biomarkers: The effectiveness of immunotherapy is being enhanced by developments in diagnostics, including liquid biopsies and biomarkers. The effectiveness of treatment and patient selection are enhanced by ongoing advancements in next-generation sequencing and artificial intelligence. Additionally, growing patient and healthcare provider knowledge is increasing the uptake and reaffirming immunotherapy's vital position in contemporary oncology.

• Focus on Combination Therapies: The increasing adoption of combination therapies and focus on biomarkers bring out the dynamic and changing landscape of cancer immunotherapy. To overcome resistance to T cell-based treatments, BioMed X and Ono Pharmaceutical teamed together to create next-generation immunotherapies that target neutrophils in solid tumours. This collaboration, hosted in Germany, invites global researchers to advance oncology innovation.

Growth Factors in the Cancer Immunotherapy Market

• Rising Need for Focused Therapies: The rising need for focused therapies due to the increasing incidences of cancer are driving growth in the cancer immunotherapy industry. While supportive regulatory regulations and quicker drug approvals are driving market expansion, ongoing breakthroughs like neoantigen-based vaccinations and bispecific antibodies are expanding treatment possibilities.

• Favorable Government Initiatives: Favorable government initiatives and easy availability of medical insurance represent some of the key factors driving the market. The existence of prestigious academic institutions and federal initiatives like Cancer Moonshot encourage market innovation. The market for immunotherapy is also growing as a result of growing clinical trials and the increasing use of combination treatments.

• Significant R&D Expenditures: The market's dominant region is the United States, mostly due to significant R&D expenditures and a robust biotechnology and pharmaceutical industry. Prostate, lung, and colorectal cancers account for 48% of cases in males and 51% in females, respectively, with 2,001,140 new cases and 611,720 deaths predicted, according to the NCI.

• Ongoing Innovations in Therapy Types: The major players are investing in novel treatments like immune checkpoint inhibitors, CAR-T cell therapies, and cancer vaccines. New biopharmaceutical firms are innovating targeted therapies, raising the competition level. The strategic collaborations, acquisitions, and clinical trials are shaping the market, with companies trying to enhance product pipelines and global reach.

• Increasing Patient and Healthcare Provider Knowledge: Growing patient and healthcare provider knowledge is increasing the uptake and reaffirming immunotherapy's vital position in contemporary oncology. The rising need for focused therapies due to the increasing incidences of cancer are driving growth in the cancer immunotherapy industry.

Leading Companies Operating in the Global Cancer Immunotherapy Industry

• Amgen Inc

• AstraZeneca plc

• Bayer AG

• Bristol-Myers Squibb Company

• Eli Lilly and Company

• F. Hoffmann-La Roche Ltd

• GSK plc.

• Johnson & Johnson

• Merck & Co., Inc.

• Merck KGaA

• Novartis AG

• Pfizer Inc.

• Sanofi S.A

Cancer Immunotherapy Market Report Segmentation

Breakup By Therapy Type

• Monoclonal Antibodies

• Cancer Vaccines

• Checkpoint Inhibitors

• Immunomodulators

• Others

Monoclonal antibodies lead the market with around 71.2% of market share. Growing funding for monoclonal antibody research and development (R&D) is creating new opportunities for oncology medicines businesses to expand in the market. The potential of monoclonal antibodies as a treatment for different kinds of cancer is being investigated in great detail. For example, the FDA authorised Talvey in August 2023 to treat adult patients with relapsed or refractory multiple myeloma who have had at least four lines of treatment, including immunomodulatory drugs, antiCD38 monoclonal antibodies, and proteasome inhibitors.

Breakup By Application

• Lung Cancer

• Breast Cancer

• Colorectal Cancer

• Melanoma

• Prostate Cancer

• Head and Neck Cancer

• Others

The market's largest revenue share is attributed to lung cancer. This is explained by the rising incidence of lung cancers, the growing use of immunotherapy, and the existence of a strong pipeline of research candidates. Additionally, new product releases and growing product approval are giving the market an optimistic outlook. For example, the US Food and Drug Administration (FDA), in November 2023 authorized Augtyro (Bristol, Inc.) to market Repotrectinib for the treatment of locally refractory or metastatic Non-Small Cell Lung Cancer (NSCLC).

Breakup By End User

• Hospitals

• Cancer Research Centers

• Clinics

• Others

Hospitals lead the market with around 68.2% of market share. With cases of cancer growing, increasing rates of treatment, and most hospitals offering immunotherapies, more patients are being admitted to a hospital. Immunotherapies, these days, are widely being used to treat cancer by the hospitals. According to the National Cancer Institute, 25% of patients died in a hospital in the United States, while 62% were hospitalized for the cancer treatments at least one time in the last month of their lives.

Breakup By Region

• North America (United States, Canada)

• Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)

• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)

• Latin America (Brazil, Mexico, Others)

• Middle East and Africa

North America accounted for the largest market share of over 45.2%. The growth in the region is due to increasing patients affected by cancer, rapid development of bioinformatic tools, and the government's initiatives that are favorable to such technologies. GLOBOCAN estimates reveal that approximately 2,281,658 new cancer cases are diagnosed, and 612,390 deaths are caused due to cancer in the US alone. Additionally, the presence of leading companies operating in this region is also driving this market. According to an article published by Elsevier Ltd, the U.S. National Cancer Institute published its envisioned national cancer plan, a roadmap, and calls to action on how to improve all stages of care for those afflicted with cancer.

In 2025, the United States accounted for 92.70% of the North America cancer immunotherapy market. Robust healthcare investments and innovative research are propelling the U.S. cancer immunotherapy market. The National Cancer Institute states that the U.S. allocated over USD 7.22 Billion to cancer research, which helps promote the advancement of immunotherapy. CAR-T therapies, such as Novartis's Kymriah will continue to gain traction. Main market leaders in this arena are Merck (Keytruda) and Bristol-Myers Squibb (Opdivo), accounting for more than 60% of immunotherapy revenues in the U.S. market. FDA approvals and government programs, such as the Cancer Moonshot, will help increase the progress in the field by two times within a couple of years. The U.S. leads in clinical trials, as there are 2,306 active interventional cancer cell therapy clinical trials in the IO Intelligence database of the Cancer Research Institute, which reflects the national emphasis on innovative therapies. Additionally, patient assistance programs and insurance coverage expansion improve access.

Recent News and Developments in Cancer Immunotherapy Market

• October 2024: The FDA approved Bristol Myers Squibb's Opdivo (nivolumab), a PD-1 inhibitor, for perioperative treatment in resectable NSCLC. This is an immunotherapy regimen: neoadjuvant Opdivo and platinum-doublet chemotherapy, surgery, and adjuvant Opdivo monotherapy. Based on the CheckMate-77T trial, the treatment showed a 42% reduction in disease recurrence, progression, or death risk and significantly improved pCR rates compared to chemotherapy alone.

• September 2024: Amgen reported encouraging data for its DLL3-targeting Bispecific T-cell Engager (BiTE) molecule, IMDELLTRA (tarlatamab-dlle), at WCLC 2024. In the Phase 1b DeLLphi-303 study, IMDELLTRA in combination with PD-L1 inhibitors as first-line maintenance therapy for extensive-stage small cell lung cancer (ES-SCLC) demonstrated a manageable safety profile and sustained disease control.

• July 2024: AstraZeneca announced the results of ADRIATIC Phase III trial. It showed that AstraZeneca's Imfinzi, or durvalumab, highly significantly improved overall survival as well as progression-free survival in patients with limited-stage small cell lung cancer after treatment with chemoradiotherapy. This is the first global Phase III immunotherapy for a survival benefit in such a setting. The safety profile was consistent with previously reported data, and all findings will be submitted to regulatory authorities. The secondary arm of the trial, combining Imjudo, also known as tremelimumab, with Imfinzi, continues to the next analysis.

• December 2023: Oxford University Hospitals launched a new mRNA cancer vaccine trial for patients with head and neck cancers.

• December 2023: BioMed X, a German research institution announced a new joint research project with Ono Pharmaceutical Co. Ltd, a Japanese pharmaceutical company, to design next-generation immunotherapies by leveraging the antitumor effects of neutrophils.

Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.

About Us

IMARC Group is a global management consulting firm that helps the world's most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel NoD) +91 120 433 0800

United States: +1-201971-6302